Phenotypes Associated with This Genotype

Genotype
MGI:5317865

• Allelic Composition: Tg(KRT5-rtTA)1Glk/0; Tg(tetO/CMV-Tslp)#Sfz/0
• Genetic Background: involves: C3H * C57BL/6 * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

integument

epidermal spongiosis ( J:100506 )

• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis

dermatitis ( J:100506 )

• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment

• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils

• however, inflammation is not seen in the small intestine or colon

hyperkeratosis ( J:100506 )

• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including hyperkeratosis

acanthosis ( J:100506 )

• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including acanthosis

dry skin ( J:100506 )

• majority of dox treated mice exhibit a mild xerosis

reddish skin ( J:100506 )

• seen in dox treated mutants

skin lesions ( J:100506 )

• dox treated mutants exhibit skin lesions consisting of mild erythema at 2 weeks of dox treatment with progression to eczematous-like changes, including erythema, crusting, and erosions, by 3-4 weeks of dox treatment

• skin lesions are most common on the snout, postauricular region, nape of the neck and upper back

• less commonly, lesions are seen on the anterior neck and hind legs

immune system

enlarged spleen ( J:100506 )

• dox treated mutants exhibit splenomegaly

increased CD4-positive, alpha-beta T cell number ( J:100506 )

• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes

increased IgE level ( J:100506 )

• in dox treated mutants

increased IgG1 level ( J:100506 )

• in dox treated mutants

decreased IgG2a level ( J:100506 )

• in dox treated mutants

abnormal cytokine level ( J:100506 )

• dox treated mutants exhibit an increase in Th2 cytokines in effected skin

abnormal lymph node morphology ( J:100506 )

• dox treated mutants exhibit a 14-fold increase in IL-4 producing cells in the skin-draining lymph nodes and an 18-fold increase in the intestinal mesenteric lymph nodes

enlarged lymph nodes ( J:100506 )

• dox treated mutants exhibit lymphadenopathy

conjunctivitis ( J:100506 )

• a few dox treated mice exhibit conjunctivitis

dermatitis ( J:100506 )

• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment

• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils

• however, inflammation is not seen in the small intestine or colon

hematopoietic system

enlarged spleen ( J:100506 )

• dox treated mutants exhibit splenomegaly

increased CD4-positive, alpha-beta T cell number ( J:100506 )

• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes

increased IgE level ( J:100506 )

• in dox treated mutants

increased IgG1 level ( J:100506 )

• in dox treated mutants

decreased IgG2a level ( J:100506 )

• in dox treated mutants

homeostasis/metabolism

epidermal spongiosis ( J:100506 )

• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis

abnormal cytokine level ( J:100506 )

• dox treated mutants exhibit an increase in Th2 cytokines in effected skin

vision/eye

conjunctivitis ( J:100506 )

• a few dox treated mice exhibit conjunctivitis

growth/size/body

enlarged spleen ( J:100506 )

• dox treated mutants exhibit splenomegaly

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
atopic dermatitis		DOID:3310	OMIM:603165 OMIM:PS603165	J:100506